EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, announced today that the European Patent Office has issued patent number 1425019 entitled “Pharmaceutical Composition.” This patent provides coverage for the pharmaceutical composition process and method of use of testosterone as a gel as well as other androgens, incorporating Bentley’s CPE-215® drug delivery technology. Issued from an application submitted on April 21, 2003, the new European patent provides proprietary protection to Bentley for 20 years from the date of filing.
